Inhibition of soluble TNFa in conjunction with anti‐amyloid immunotherapy

Abstract

Background: The approval of anti‐amyloid beta immunotherapies have showcased breakthroughs in our understanding and treatment of Alzheimer's disease (AD). While promising, anti‐amyloid beta (Aß) immunotherapies may lead to the development of ARIA (Amyloid Related Imaging Abnormalities).

The paper